A Novel Tumor-Promoting Function Residing in the 5′ Non-coding Region of vascular endothelial growth factor mRNA

Background Vascular endothelial growth factor-A (VEGF) is one of the key regulators of tumor development, hence it is considered to be an important therapeutic target for cancer treatment. However, clinical trials have suggested that anti-VEGF monotherapy was less effective than standard chemotherapy. On the basis of the evidence, we hypothesized that vegf mRNA may have unrecognized function(s) in cancer cells. Methods and Findings Knockdown of VEGF with vegf-targeting small-interfering (si) RNAs increased susceptibility of human colon cancer cell line (HCT116) to apoptosis caused with 5-fluorouracil, etoposide, or doxorubicin. Recombinant human VEGF165 did not completely inhibit this apoptosis. Conversely, overexpression of VEGF165 increased resistance to anti-cancer drug-induced apoptosis, while an anti-VEGF165-neutralizing antibody did not completely block the resistance. We prepared plasmids encoding full-length vegf mRNA with mutation of signal sequence, vegf mRNAs lacking untranslated regions (UTRs), or mutated 5′UTRs. Using these plasmids, we revealed that the 5′UTR of vegf mRNA possessed anti-apoptotic activity. The 5′UTR-mediated activity was not affected by a protein synthesis inhibitor, cycloheximide. We established HCT116 clones stably expressing either the vegf 5′UTR or the mutated 5′UTR. The clones expressing the 5′UTR, but not the mutated one, showed increased anchorage-independent growth in vitro and formed progressive tumors when implanted in athymic nude mice. Microarray and quantitative real-time PCR analyses indicated that the vegf 5′UTR-expressing tumors had up-regulated anti-apoptotic genes, multidrug-resistant genes, and growth-promoting genes, while pro-apoptotic genes were down-regulated. Notably, expression of signal transducers and activators of transcription 1 (STAT1) was markedly repressed in the 5′UTR-expressing tumors, resulting in down-regulation of a STAT1-responsive cluster of genes (43 genes). As a result, the tumors did not respond to interferon (IFN)α therapy at all. We showed that stable silencing of endogenous vegf mRNA in HCT116 cells enhanced both STAT1 expression and IFNα responses. Conclusions These findings suggest that cancer cells have a survival system that is regulated by vegf mRNA and imply that both vegf mRNA and its protein may synergistically promote the malignancy of tumor cells. Therefore, combination of anti-vegf transcript strategies, such as siRNA-based gene silencing, with anti-VEGF antibody treatment may improve anti-cancer therapies that target VEGF.


A B S T R A C T
Background Vascular endothelial growth factor-A (VEGF) is one of the key regulators of tumor development, hence it is considered to be an important therapeutic target for cancer treatment. However, clinical trials have suggested that anti-VEGF monotherapy was less effective than standard chemotherapy. On the basis of the evidence, we hypothesized that vegf mRNA may have unrecognized function(s) in cancer cells.

Methods and Findings
Knockdown of VEGF with vegf-targeting small-interfering (si) RNAs increased susceptibility of human colon cancer cell line (HCT116) to apoptosis caused with 5-fluorouracil, etoposide, or doxorubicin. Recombinant human VEGF 165 did not completely inhibit this apoptosis. Conversely, overexpression of VEGF 165 increased resistance to anti-cancer drug-induced apoptosis, while an anti-VEGF 165 -neutralizing antibody did not completely block the resistance. We prepared plasmids encoding full-length vegf mRNA with mutation of signal sequence, vegf mRNAs lacking untranslated regions (UTRs), or mutated 59UTRs. Using these plasmids, we revealed that the 59UTR of vegf mRNA possessed anti-apoptotic activity. The 59UTR-mediated activity was not affected by a protein synthesis inhibitor, cycloheximide. We established HCT116 clones stably expressing either the vegf 59UTR or the mutated 59UTR. The clones expressing the 59UTR, but not the mutated one, showed increased anchorage-independent growth in vitro and formed progressive tumors when implanted in athymic nude mice. Microarray and quantitative real-time PCR analyses indicated that the vegf 59UTR-expressing tumors had up-regulated anti-apoptotic genes, multidrug-resistant genes, and growthpromoting genes, while pro-apoptotic genes were down-regulated. Notably, expression of signal transducers and activators of transcription 1 (STAT1) was markedly repressed in the 59UTR-expressing tumors, resulting in down-regulation of a STAT1-responsive cluster of genes (43 genes). As a result, the tumors did not respond to interferon (IFN)a therapy at all. We showed that stable silencing of endogenous vegf mRNA in HCT116 cells enhanced both STAT1 expression and IFNa responses.

Conclusions
These findings suggest that cancer cells have a survival system that is regulated by vegf mRNA and imply that both vegf mRNA and its protein may synergistically promote the malignancy of tumor cells. Therefore, combination of anti-vegf transcript strategies, such as siRNA-based gene silencing, with anti-VEGF antibody treatment may improve anti-cancer therapies that target VEGF.

Introduction
Vascular endothelial growth factor-A (VEGF) is one of the key regulators in tumor formation and progression [1][2][3][4]. The clinical significance of VEGF in tumors has been demonstrated by many studies showing that the VEGF expression level is correlated with tumor grade, depth of invasion, status of nodal and distant metastasis, and clinical stage [5][6][7][8][9][10]. In addition, high levels of circulating VEGF are associated with resistance to chemotherapy in patients with metastatic solid tumors, including colorectal cancer [11,12]. The stimulatory action of VEGF on tumor angiogenesis is believed to play a central role in promotion of tumor development. At the same time, VEGF is known to act as an autocrine survival and growth factor for tumor cells [13]. Based on the evidence outlined above, a number of strategies to target VEGF or VEGF receptors (VEGFR) have been developed and subjected to clinical evaluation [14]. In contrast to preclinical studies in animal models, clinical trials suggest that anti-VEGF monotherapy was less effective than standard chemotherapy [15], raising the possibility that VEGF or possibly vegf mRNA might possess unrecognized function(s).
A recent report has shown that VEGF protein functions as an internal autocrine survival factor in human breast cancer cells through internally expressed VEGFR [16]. In addition, non-coding RNAs have now been recognized to play critical roles in tumorigenesis [17]. One class of the tumor-associated non-coding RNAs is the untranslated region (UTR) of certain mRNAs, including the 39UTR of a-tropomyosin mRNA [18], the 39UTR of prohibitin mRNA [19], the 39UTR of ribonucleotide reductase mRNA [20], and the 59UTR of c-myc mRNA [21]. All of these UTR RNAs function as tumor suppressors. From this point of view, we directed our attention to a unique structure of vegf mRNA characterized by its unusually long 59UTR (1,038 nucleotide [nt]) containing two internal ribosome entry sites (IRES) [22,23].

Cell Culture and Transfection
The human colon carcinoma cell lines (HCT116 and RKO) were maintained in McCoy's 5A medium, supplemented with 10% (v/v) FCS and antibiotics. The human embryonic kidney cell line (HEK293) was maintained in DMEM medium, supplemented with 10% (v/v) FCS and antibiotics. The human gastric carcinoma cell line (AGS) was maintained in F-12 medium, supplemented with 10% (v/v) FCS and antibiotics. Amounts of VEGF 165 secreted into the culture medium were measured by ELISA assay (Quantikine, R&D Systems), according to the manufacturer's instructions.
Transfection of cells was performed using the jetPEI (Polyplus-transfection) or FuGENE HD (Roche Diagnostics) transfection reagent, according to the manufacturer's instructions. We checked the transfection efficiency by monitoring expression of yellow fluorescent protein (YFP)expressing plasmid and determined the efficiency to be 60%-65% in HCT116 cells, 80%-85% in HEK293 cells, 60%-65% in RKO cells, and 60%-65% in AGS cells.

Cell Growth
Cell growth was assessed using a CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega), according to the manufacturer's instructions. Cells were plated in a 96-well flat-bottom plate and cultured in 100 ll of McCoy's 5A medium containing 10% (v/v) FCS and antibiotics, and the MTT reagent (20 ll/well) was added to each well and incubated for 1 h. The levels of blue formazan were measured spectrophotometrically at 490 nm at each time point using a microplate reader (Wallac 1420 ARVO MX; Perkin Elmer).
To assess anchorage-independent growth, cells (1 3 10 5 ) were plated in 2 ml of McCoy's 5A medium containing 10% (v/v) FCS and 0.33% agar. This suspension was layered over a 3-ml base layer of solidified McCoy's medium containing 10% (v/v) FCS and 0.5% agar in 60-mm diameter culture dishes. Following a 28-d incubation at 37 8C in 5% CO 2 , the number of colonies (approximately .0.1 mm in diameter) with dense centers was scored for each plate.

Assessment of Apoptosis
Apoptotic cells were assessed by the TUNEL-staining method using an in situ Cell Death Detection kit (Roche Diagnostics). TUNEL-positive cells were viewed using a microscope, and percentages of the positive cells were calculated. A minimum of 300 cells was counted for each determination. Apoptosis was also detected using the APOPercentage apoptosis assay kit (Biocolor), according to the manufacturer's instructions. The APOPercentage dye stains cells undergoing the membrane ''flip-flop'' event when phosphatidylserine is translocated to the outer leaflet. This event is specific for apoptosis, but not for necrosis.
The caspase 3/7 activity was measured using the Caspase-Glo 3/7 assay (Promega), according to the manufacturer's instructions. After cells were treated with 80 lM of 5fluorouracil (5-FU) for 24 h, the Caspase-Glo 3/7 reagent was added to each well and incubated for 1 h. The luminescence was measured using a microplate-reading luminometer (Wallac 1420 ARVO MX; Perkin Elmer).
As a control siRNA-expressing plasmid, we used the pcDNA6.2-GW/EmGFP-miR-negative control plasmid expressing mature siRNA that is predicted not to target any known vertebrate genes (Invitrogen).
p165mSPHA 39 and p165AUGmSPHA have H9D and L14E mutations in the signal sequence that prevent secretion of the VEGF 165 protein. p165mSPHA 39 was digested with ClaI and ApaI, blunted by Klenow treatment, and religated. The resulting plasmid (p165mSPHA, construct III in Figure 2A) did not contain the 39UTR sequence. p165mSPHA 39 was digested with XbaI and NgoMIV, blunted by Klenow treatment, and religated. The resulting plasmid (pAUG165mSPHA 39, construct IV) did not encode the 59UTR sequence. Several deletion constructs of the vegf 59UTR were also made from the pVC plasmid by digestion with NgOMIV (construct VI), XbaI and NheI (construct VII), or BamHI (construct VIII). We also prepared a plasmid encoding full-length vegf mRNA with an intact signal peptide sequence. The construct pVC, which has an intact signal sequence, was digested with NarI and BsaBI, and the resultant NarI-BsaBI fragment was ligated into p165mSPHA 39 to reconstruct full-length vegf mRNA with an intact signal peptide sequence (p165HA 39). A construct mutated between nt 591 and nt 746 of the vegf 59UTR was synthesized using two serial double-stranded DNA fragments (mutations are indicated by lower case letters): nt 576 -GCG AGC CGC GGG CAa GGa CCa GAa CCa GCa CCa GGg GGa GGa GTa GAa GGa GTa GGG GCT C-nt 636 and nt 637-GGGCT CGa GGa GTa GCa tta AAg CTa TTt GTa CAg tta tta GGa TGc TCa CGa TTt GGg GGg GCa GTa GTa aga GCa GGa GAg GCa GAa CCa AGt GGg GCa GCa AGg AGT GCT AGC-nt 752. The two synthesized fragments were ligated and inserted into pVC digested with SacII and NheI to generate plasmid pVCmut (construct X in Figure 2A). All the constructs were confirmed to have the expected sequences using a DNA sequencer. The secondary structures of vegf 59UTR and its mutant were analyzed using the mfold 3.2 algorithm of Zuker [28].
We also constructed a plasmid expressing a chimeric mRNA comprising the vegf 59UTR fused to YFP. The constructs pVC and pVCmut were digested with EcoRI and NcoI, and the resulting EcoRI-NcoI fragments were ligated into pd2EYFP-N1 (Clontech) to generate pVY and pVYmut, respectively.

Western and Northern Blot Analyses
Cell lysates were prepared using a lysis buffer containing 100 mM Tris-HCl (pH 6.8), 300 mM NaCl, 2 mM EDTA, and 4% (v/v) SDS. Western immunoblotting was performed as described previously [29] using a rabbit polyclonal antihuman influenza virus hemagglutinin (HA) Ab (Santa Cruz Biotechnology) at a 1/1,000 dilution, a mouse monoclonal Ab against human signal transducers and activators of transcription 1 (STAT1) (Cell Signaling) at a 1/1,000 dilution, a rabbit polyclonal anti-L-VEGF Ab at a 1/500 dilution (a gift from Hervé Prats) [26], or a mouse anti-b-actin monoclonal Ab (Sigma). The specificity of individual antibody reactivity was confirmed by the absorption test with the corresponding antigen peptide ( Figure S10). Blocking antigen peptide for human STAT1 and HA were obtained from Cell Signaling and Santa Cruz Biotechnology, respectively. Antigen peptides for L-VEGF were synthesized using an Applied Biosystems 432A peptide synthesizer.
Total RNA was prepared by the guanidinium thiocyanate method. Northern hybridization was performed as described previously [29] using following cDNA probes. cDNA probes for vegf 59UTR RNA and vegf ORF RNA were prepared by digestion of the plasmid p165mSPHA 39 with NgoMIV and ClaI, and SacII and NheI, respectively. A cDNA probe for CAT mRNA was prepared as a digestion fragment of the plasmid pVC using EcoRI and BglII sites. These probes were labeled with [a-32 P]dCTP using Klenow enzyme (New England BioLabs), according to the manufacturer's instructions.

Animal Studies and Immunohistochemistry
The use of animals in the experiments described here was approved by the Animal Care Committee of University of Tokushima. Seven-wk-old male athymic nude mice (Nippon SLC) were caged in groups of five and acclimated for 1 wk. A cell suspension (5 3 10 6 cells) in serum-free McCoy's 5A medium, prepared from each stably transfected clone, was injected subcutaneously into the flanks of nude mice. The sizes of tumors that developed in the injected mice were measured in two dimensions with a caliper and their volumes calculated using the formula (L 3 W 2 ) 3 0.5, where L is length and W is width. We confirmed that parental HCT116 cells (5 3 10 6 cells) injected subcutaneously into nude mice formed tumors whose volumes were around 500 mm 3 day 28 after transplantation. Therefore, HCT116/YFP clones appeared to form xenograft tumors less efficiently than parental HCT116 cells, probably because expression of YFP and/or procedures during the establishment of permanent cell cloning was likely to nonspecifically reduce the tumor-forming capability.
Some mice were injected intraperitoneally with BrdU (1.5 g/kg body weight, Sigma-Aldrich) 2 h before they were humanely killed. The mice were killed on the indicated days, and growing tumors were removed and fixed with formalin in PBS. The fixed xenografts were sectioned and stained with hematoxylin and eosin (HE), or by immunohistochemistry using a mouse monoclonal anti-BrdU Ab (Sigma-Aldrich), or by a DeadEnd colorimetric TUNEL System (Promega). Vasculature was stained using a rat anti-mouse CD31 Ab (BD Pharmingen).
We also examined the effects of 5-FU on implanted tumors. In this experiment, HCT116/vegf 59 transfectants (5 3 10 6 cells) were injected subcutaneously into the left flanks of nude mice, and HCT116/YFP (1 3 10 7 cells) or HCT116/vegf 59mut transfectants (1 3 10 7 cells) were injected into the right flanks of the same mice. When the tumors reached a size of approximately 40 mm 3 , usually by day 7, the mice were treated daily with an intraperitoneal injection of 5-FU (30 mg/kg weight, Sigma-Aldrich), or with 5-FU (30 mg/kg weight) plus IFNa (50,000 U/mouse; PBL Biomedical Laboratories). The tumor sizes were measured daily using a caliper, and their volumes were calculated as described above.

Microarray Analysis
We used Agilent Human 1A oligomicroarrays (Agilent Technologies) containing 60-mer DNA probes synthesized in situ in a 22-k format. Total RNA was prepared from three independent vegf 59-G5 tumors on day 14, and an equal amount of RNA from each tumor was mixed. After contaminating DNA had been removed using a DNase kit (Qiagen), the resultant RNA quality was evaluated using the Agilent 2100 Bioanalyzer (Agilent Technologies). Total RNA was also prepared from three vegf 59mut-D5 tumors on day 14 in the same manner. Synthesis, amplification, and labeling of cRNA were carried out in accordance with the manufacturer's protocol. Cy5-cRNA (0.75 lg) prepared from vegf 59-G5 tumors was mixed with the same amount of Cy3-cRNA from vegf 59mut-D5 tumors. Hybridization was performed on the Agilent Human 1A oligomicroarray (Agilent Technologies), according to the manufacturer's protocol. Fluorescence images of the hybridized microarrays were obtained using an Agilent microarray scanner (G2565BA). Signal intensities of Cy5 and Cy3 were quantified and analyzed by subtracting the backgrounds using feature extraction software (Agilent, version 9.5). The Cy5/Cy3 ratios of 12,178 genes that had a higher fluorescence value than 100 for both Cy5 and Cy3 signals were transformed to logarithms for global normalization. We selected genes whose mRNA levels differed by .2fold between vegf 59-G5 and mut-D5 tumors.

Dual-Luciferase Assay
To measure IRES activity, we used the bicistronic plasmid. The bicistronic cassette expresses the LucR in a cap-dependent manner and LucF in an IRES-dependent manner. Each IRES or hairpin control is located between the two cistrons.
To measure IFN-dependent transcriptional activity, we used plasmids containing the motifs IFN-stimulated regulatory element (ISRE) and IFN-c-activated sequence (GAS) upstream of the LucF reporter gene (Pathway Profiling Luciferase System).
LucF and LucR activities were measured using the Dual-Luciferase reporter assay system (Promega), according to the manufacturer's instructions. Transfected cells were rinsed twice with PBS, scraped, and homogenized in 50 ll of lysis reagent provided with the kit. The lysate was cleared by a 2min centrifugation at 4 8C. Chemiluminescent signals were measured in a luminometer (Wallac 1420 ARVO MX; Perkin Elmer) equipped with automatic injectors.

Statistical Analysis
The data were analyzed using the two-tailed Student's t-test or ANOVA and the Scheffé 's test. A p-value of less than 0.05 was considered significant.

Effect of vegf mRNA on Apoptosis Caused with Anti-Cancer Drugs
First, we investigated whether vegf mRNA possessed a tumor-promoting activity in HCT116 cells that expressed VEGFR-2 and Neuropilin-1, À2 ( Figure S6) and secreted spontaneously VEGF 165 at 759 6 32 pg/ml (mean 6 SD, n ¼ 4). Two different vegf-targeting siRNAs successfully knocked down endogenous vegf mRNA in HCT116 cells ( Figure 1A). This silencing made the cells susceptible to apoptosis caused with a low concentration of 5-FU (20 lM). We then examined the effect of supplementation of rhVEGF 165 in the knockdown cells. The amount of secreted VEGF 165 increased to 1,018 6 48 (n ¼ 4) from the cells that were untransfected and treated with 5-FU (20 lM) for 48 h. An external supplementation of 1,000 pg/ml rhVEGF 165 failed to block the 5-FUinduced apoptosis in vegf siRNA-transfected cells ( Figure 1B). Treatment with rhVEGF 165 at 2,000 pg/ml or higher significantly, but not completely, prevented the apoptosis.
In contrast, cells were transiently transfected with a plasmid expressing full-length vegf 165 mRNA and exposed to a higher concentration of 5-FU (80 lM). These cells secreted VEGF 165 (7,092 6 23 pg/ml, n ¼ 4) during the experimental period and exhibited resistance to 5-FU-induced apoptosis ( Figure 1C). It should be noted that anti-VEGF 165 -neutralizing monoclonal Ab could not completely cancel the anti-apoptotic activity even at concentrations of up to 5 lg/ml (about 250 molar excess amount of secreted VEGF 165 ) ( Figure  1C). Both knockdown and overexpression experiments suggest that both VEGF protein and vegf mRNA may possess an anti-apoptotic function. Similar or even clearer results were observed in the cells treated with other anti-cancer drugs, etoposide and doxorubicin ( Figure S1A and S1B).
Effect of vegf mRNA 59UTR on Apoptosis Caused by 5-FU Next, we used the mutated full-length vegf 165 mRNAexpressing plasmid that has mutations of two amino acid residues within the signal peptide, shown as ''mSP'' in construct II (Figure 2A). This plasmid-derived mRNA is translated into a nonsecreted VEGF 165 protein [26]. We confirmed that cells transfected with this construct expressed full-length vegf mRNA and VEGF 165 protein ( Figure S2A), but did not secrete detectable amounts of the plasmid-derived VEGF 165 (unpublished data). As was described above, HCT116 cells overexpressing full-length vegf 165 mRNA without mutation were completely resistant to 80 lM 5-FU ( Figure 1C). In contrast, cells transfected with construct II significantly, but not completely, blocked the 5-FU-induced apoptosis ( Figure  2B and Figure S3A). This partial loss of anti-apoptotic activity was probably due to the lack of VEGF 165 -secreting activity. Next, we prepared the constructs lacking the 39UTR (construct III), 59UTR (construct IV), or both (construct I), and found that the 59UTR was associated with the chemoresistant phenotype ( Figure 2B). Similar results were observed in the cells treated with other anti-cancer drugs, etoposide and doxorubicin ( Figure S1C and S1D).
To confirm the functional role of the 59UTR, we used a plasmid expressing the vegf 59UTR fused to CAT coding gene ( Figure 2A, construct V), which does not express VEGF protein. This chimeric mRNA retained the resistance to 5-FU ( Figure 2C). We then designed several deletion constructs of the chimeric mRNA (constructs VI-VIII in Figure 2A), and found that the 270-nt-long element delimited by positions nt 475 and nt 745 in the 59UTR sequence was crucial for the drug-resistance phenotype ( Figure 2C). This sequence is just upstream of IRES-A, but does not require the IRES activity [22].
It is known that the 59UTR of human vegf mRNA encodes long N-terminal VEGF proteins (termed L-VEGF) that are translated from CUG codons upstream of and in-frame with the classical AUG start codon [24]. To eliminate the possibility that the L-VEGF proteins might induce the chemoresistance, we designed a mutated 59UTR construct that produced L-VEGF protein, but modified the RNA structure by substituting the nucleic acid sequence between nt 591 and nt 746 (construct X in Figure 2A). Secondary structures of the vegf 59UTR and its mutated 59UTR were predicted by mFold program ( Figure S5). The mutation changed the secondary structure of several parts and ablated a stem-loop structure that is located in the functional region of the vegf 59UTR (nt 699 to nt 738) as described above. The mutated construct X produced L-VEGF protein ( Figure S2B), but did not induce the resistance to 5-FU ( Figure 2C). We also used a simply mutated 59UTR, in which the first CUG codon was substituted into a noninitiating UUU codon (construct XI in Figure 2A) [24]. This mutant did not produce L-VEGF protein ( Figure S2B), but was able to induce the resistance as efficiently as did the wild-type 59UTR ( Figure 2C). We further examined the effect of a protein synthesis inhibitor, cycloheximide (CHX). To determine the inhibitory effect of CHX, HCT116 cells were transfected with plasmid encoding luciferase in the absence or presence of CHX, and luciferase activity was measured. Protein synthesis was blocked by 86 6 5% (mean 6 SD, n ¼ 3) and 94 6 3% (mean 6 SD, n ¼ 3) with 1 and 10 lg/ml CHX, respectively. As shown in Figure 2D, both full-length vegf mRNA (construct II) and vegf 59UTR-CAT mRNA (construct V) efficiently inhibited 5-FU-induced apoptosis even in the presence with 10 lg/ml CHX. These results suggest that the 59UTR-mediated chemoresistance may not require de novo protein synthesis.
In addition to the TUNEL-staining method, we evaluated the vegf 59UTR-mediated anti-apoptotic effect by the Apopercentage-staining method ( Figure S3C) and by measuring activities of caspase 3 and caspase 7 ( Figure S3D), which are crucial effector enzymes for apoptosis induced by genotoxic agents. We confirmed that the results obtained by the Apopercentage-staining method were similar to those by the TUNEL assay ( Figure S3B and S3C). Cells transfected with construct II, V, and XI significantly, but not completely, blocked the activation of caspase 3/7 ( Figure S3D).
To examine whether this anti-apoptotic function is peculiar to vegf mRNA 59UTR, we used three 59UTRs containing IRES (c-myc, bip, and fgf-2 mRNA 59UTRs) [30] and the pdgf-b mRNA 59UTR that is unusually long, but does not contain IRES activity [31]. After transfection with plasmid expressing one of the indicated 59UTR-CAT mRNAs, apoptosis was assessed by the TUNEL-staining method. Only the vegf 59UTR induced the resistance to 5-FU among 59UTRs tested ( Figure S4).
We also examined whether the vegf 59UTR similarly induce the chemoresistance in other human cancer cell lines (RKO, HEK293, and AGS cells), and confirmed that both full-length vegf mRNA and vegf 59UTR RNA induced 5-FU resistance in these cells. (Figure S6B-S6D). These observations suggest that the vegf 59UTR function is not peculiar to HCT116 cells.
The vegf 59UTR contains IRES sequences that interact with IRES-binding factors and regulate translation initiation in a cap-independent manner [22,23]. Many IRES-containing mRNAs encode proteins that regulate cell growth, differentiation, and apoptosis [30,32]. Thus, overexpression of the vegf 59UTR raises the possibility that increased amounts of the vegf 59UTR may trap IRES-binding factors, thereby nonspecifically modifying IRES-dependent expression of genes. To address this issue, we tested the effect of vegf 59UTR on other IRES activities ( Figure S7B). HCT116 cells were cotransfected with plasmids expressing vegf 59UTR-CAT mRNA (construct V or mutated construct X in Figure 2A) and the bicistronic construct containing 59UTR of the indicated genes. We confirmed that overexpression of the vegf 59UTR RNA did not repress the IRES activity of bip, c-myc, or fgf-2 59UTR ( Figure S7B).

Characterization of HCT116 Cells Stably Expressing vegf 59UTR
To investigate chronic effects of the vegf mRNA 59UTR on malignant transformation of HCT116 cells both in vitro and in vivo, we established stable transfectants that expressed chimeric mRNAs of either the vegf 59UTR or the mutant one (as described above) fused to the YFP coding gene. Use of these chimeric mRNAs had the following advantages: (i) they did not produce VEGF protein, (ii) expression of these elements could be monitored by YFP fluorescence, and (iii) the chimeric mRNAs were translated similarly as vegf mRNA in our cell system. Ectopic mRNAs were equally expressed in corresponding cell lines and did not modify the amounts of endogenous vegf mRNA and VEGF among the clones ( Figure  S8A and S8B).

Tumor-Forming Activity of the HCT116/vegf 59 Clones
To demonstrate the malignancy of HCT116/vegf 59 in vivo, athymic nude mice were injected subcutaneously with each clone, and growing tumor masses were measured. Both HCT116/vegf 59mut and control HCT116/YFP formed small tumor masses that did not expand further (vegf 59mut-tumor and YFP-tumor, respectively). In contrast, HCT116/vegf 59 rapidly and progressively formed tumors (vegf 59-tumor). The average volumes of the vegf 59-tumors were 4-fold and 41-fold larger than those of the control YFP-tumors on days 5 and 28, respectively ( Figure 4B). There was no significant difference between the sizes of tumors derived from vegf 59-G3 clone and -G5 clone at either time point.
Histological examination showed that the growing vegf 59tumors contained central necrotic areas, while the vegf 59muttumors formed a small nest of tumors encapsulated by connective tissue (Figure 4C). We next tested whether the accelerated growth of the vegf 59-tumors was a consequence of enhanced proliferation, decreased apoptosis, or both. Apoptosis and proliferation were assessed by quantifying TUNELpositive and BrdU-incorporating cells, respectively ( Figure  4C). The vegf 59-tumors showed a small, but significant increase in the numbers of BrdU-positive cells ( Figure 4D) compared with the vegf 59mut-tumors. The number of apoptotic cells in the vegf 59-tumor was significantly lower than in the vegf 59mut-tumor ( Figure 4D). These results suggest that the vegf 59UTR RNA may accelerate tumor growth by suppression of apoptosis and promotion of cell growth. We also examined the development of tumor vessels by staining with an Ab against an endothelial cell marker CD31. The vegf 59-tumors significantly increased CD31positive microvessels ( Figure 4C) in association with enlargement of the tumors, compared with the vegf 59mut-tumors.

Changes in Gene Expression in the vegf 59-Tumors
Total RNA was prepared on day 14 from three different vegf 59-tumors, and an equal amount of RNA from each tumor was mixed. Total RNA was also prepared from three different vegf 59mut-tumors in the same manner. Using a microarray technique, gene expression profiles were compared between the two RNA samples. The vegf 59-tumors up-regulated mRNA expression of 377 genes and down-regulated 295 genes .2fold, compared with the vegf 59mut-tumors (see gene lists in Tables S1 and S2). One of the distinctive identifying features of the listed genes was that the vegf 59-tumors selectively down-regulated pro-apoptotic genes (eight genes) and upregulated anti-apoptotic genes (five genes). Quantitative RT-PCR validated the significant up-regulation of an antiapoptotic gene (mia) and down-regulation of pro-apoptotic genes (fas, pcdc1, nrg1, and bax) ( Table 1).
It should also be noted that a major set of IFN-inducible genes (43 genes) were specifically down-regulated in the vegf 59-tumors (Table 2), whereas none of IFN-inducible genes were included in the up-regulated genes (Table S1). Using quantitative RT-PCR, we compared mRNA levels of nine IFNinducible genes between the vegf 59-tumors and the vegf 59mut-tumors, and validated significant down-regulation of eight out of nine genes in the vegf 59-tumors (Table 1). An IFN-inducible gene stat1 encoding a critical transcription factor for both type I (a/b) and type II (c) IFNs [33] was also significantly down-regulated, suggesting specific deactivation of the IFN/STAT1 pathway in the rapidly growing vegf 59tumors.

STAT1 Expression and Responsiveness to IFNs
To confirm that the vegf mRNA 59UTR selectively deactivated the IFN-dependent pathway in vitro, we measured the levels of stat1 mRNA and its protein in each stable clone by quantitative RT-PCR and immunoblotting, respectively. Similar amounts of stat1 mRNA were observed among all clones ( Figure 5A). Both HCT116/YFP and HCT116/vegf 59mut cells responded to rhIFNa and up-regulated stat1 mRNA expression, but this up-regulation was not observed in the HCT116/vegf 59 clones ( Figure 5A). Consistent with these, induction of STAT1 protein by IFNa was defect in the HCT116/vegf 59cells ( Figure 5B). STAT1 plays a crucial role in the expression of the majority of IFN-inducible genes [34]. We therefore tested whether the HCT116/vegf 59 cells actually showed decreased STAT1dependent transcriptional activity. For this purpose, we used two different STAT1-dependent reporter plasmids encoding a promoter that either contained ISRE-binding sites (pISRE-Luc) that mainly respond to IFNa or GAS-binding sites (pGAS-Luc) that preferentially respond to IFNc. Each stable clone was transiently transfected with pISRE-Luc or pGAS-Luc reporter plasmid, and then they were treated with rhIFNa or rhIFNc for 24 h. In the HCT116/vegf 59 clones, there was significant impairment of the IFNa-stimulated response of ISRE ( Figure 5C) and the IFNc-dependent response of GAS ( Figure 5D) compared to the HCT116/vegf 59mut clones or to the HCT116/YFP cells ( Figure 5C and 5D). We confirmed that the IFN receptors were equally expressed in all clones tested (FigureS9A). These results suggest that the IFNa pathway might be more severely impaired than the IFNc pathway. We also measured the levels of endogenous IFNa, b, and c mRNAs in each clone by quantitative RT-PCR. There was no difference in the level of IFNa mRNA in each clone ( Figure S9B). Neither clone expressed detectable amounts of IFNb or IFNc mRNAs.
We further examined the effects of stable knockdown of endogenous vegf mRNA on STAT1 expression in HCT116 cells (HCT116/siVEGF). Endogenous vegf mRNA was successfully silenced in the HCT116/siVEGF clones ( Figure 6A). As shown in Figure 6B, the basal and the IFNa-stimulated expression levels of STAT1 were significantly increased in the HCT116/siVEGF clones compared with the control clone (HCT116/siControl) and parental cells (HCT116). Consistent with these results, both the basal and the IFNa-stimulated ISRE-dependent transcriptional activities were increased 2to 3-fold in the HCT116/siVEGF clones ( Figure 6C).

Impairment of the IFNa-Dependent Anti-apoptotic Pathway in Growing vegf 59-Tumors
To assess whether the reduced IFN signals were responsible for the malignant transformation of the HCT116/vegf 59 cells, we examined the effect of IFNs on 5-FU-induced apoptosis, as IFNs are known to potentiate the pharmacological action of 5-FU [35]. Treatment with rhIFNa or rhIFNc alone did not induce apoptosis in any of the clones tested, while both IFNa and IFNc significantly enhanced 5-FU-induced apoptosis in the HCT116/vegf 59mut cells or the HCT116/YFP cells ( Figure  5E and 5F). In contrast, neither IFNa nor IFNc had an effect in the HCT116/vegf 59 cells.
Finally, we examined whether growing vegf 59-tumors had impaired responses to IFNa in vivo. We therefore focused on the effects of rhIFNa on tumor growth. For these experiments, we implanted HCT116/vegf 59 (5 3 10 6 cells) in the left flank and either HCT116/YFP (1 3 10 7 cells) or HCT116/vegf 59mut (1 3 10 7 cells) in the right flank of the same animal. When both tumors reached approximately 40 mm 3 on day 7, we started to treat the mouse once a day with 5-FU (30 mg/kg body weight) or with a combination of 5-FU (30 mg/kg body weight) and rhIFNa (50,000 U). At day 4 in the YFP-tumors ( Figure 7A) or day3 in the vegf 59mut-tumors ( Figure 7C) after the 5-FU treatment, the YFP-tumors and the vegf 59muttumors began to reduce in size, respectively. Simultaneous treatment with rhIFNa accelerated this reduction and most tumors disappeared within 7 d. In contrast, the responses of the vegf 59-tumors to 5-FU and rhIFNa were strikingly different. Treatment with 5-FU initially and transiently decreased tumor sizes, but they then began to grow rapidly from day 4 ( Figure 7B). Simultaneous administration of rhIFNa did not have any effect on tumor growth.

Discussion
In the present study, we show a novel function of the vegf 59UTR in tumor cell survival and growth. Both treatment of vegf-knockdown HCT116 cells with rhVEGF 165 and treatment of VEGF 165 -overexpressing HCT 116 cells with a neutralizing anti-VEGF 165 Ab suggest the presence of vegf mRNAmediated anti-apoptotic action against anti-cancer drugs (5-FU, etoposide, and doxorubicin). We determined that the anti-apoptotic action resided in a 270-nt-long element between positions nt 475 and nt 745 of the 59 UTR of vegf mRNA. The 59 UTR could exert the anti-apoptotic action even in the presence of a protein synthesis inhibitor. These results suggest that the 59UTR may function as a regulatory RNA.
To further clarify the potential role of vegf 59UTR RNA, we established HCT116/vegf 59 and HCT116/vegf 59mut clones. HCT116/vegf 59 cells, but not HCT116/vegf 59mut cells, showed anchorage-independent growth in vitro and rapidly grew when implanted in athymic nude mice, indicating that vegf mRNA 59UTR facilitates tumor progression. The rapid growth observed in the vegf 59-tumors might be due to the acquisition of resistance to apoptosis (the process that eliminates defective cells), which contributes to tumor development and resistance to drug therapy. Microarray and quantitative RT-PCR analyses demonstrated that expression of pro-apoptotic genes (fas, pdcd1, nrg1, and bax) and an anti-apoptotic gene (mia) was up-regulated and markedly down-regulated, respectively, in the rapidly growing vegf 59tumors. In addition, microarray analysis also showed that the expression of cell growth-promoting genes (cxcl1, cxcl2, cxcr4, mia1, and fgf-19) was up-regulated in the rapidly growing vegf 59-tumors.
The combination of both dysregulated cell proliferation and suppressed cell death are required for neoplastic progression [36]. In addition, survival and growth under anchorage-independent conditions are required for the progression [37]. This anchorage-independent property of tumor cells correlates with their in vivo oncogenic potential. Thus, we consider that the vegf 59UTR may increase the ability not only to suppress apoptosis but also to survive and grow in an anchorage-independent manner, resulting in the acceleration of tumor formation. The precise sequence and structure of the 59UTR of vegf mRNA as well as the molecular target(s) that interact with the RNA remain to be elucidated. However, it seems likely that such a profound change in cell function induced by RNA would require a global change of gene expression in cells. Our results support this notion by showing that the vegf mRNA 59UTR modulated expression of numerous genes. One of the striking findings is that many of the down-regulated genes belong to a set of IFN-inducible genes, including stat1.
Since it is reported that IFN down-regulates IRES-dependent translation of distinct mRNAs [38], overexpression of the IRES-containing 59UTR might attenuate the IFN signal, leading to the down-regulation of IFN-inducible genes. We therefore tested whether IFNa affected IRES activity of c-myc, fgf-2, or bip using a bicistronic luciferase assay system ( Figure   Figure 5. Impaired Responses to IFNs in the vegf 59UTR-Expressing Clones (A and B) Repression of stat1 mRNA and its protein expression in the vegf 59UTR-expressing cells. Total RNA or whole cell extracts were prepared from the indicated clones before and 24 h after treatment with 500 U/ml rhIFNa. Levels of stat1 mRNA were measured using quantitative RT-PCR (A). Values were normalized for the amount of gapdh mRNA (means 6 SEM, n ¼ 4). Means with different superscripts are significantly different by ANOVA and Scheffé's test (p , 0.05). Amounts of STAT1a (91 kDa) and STAT1b (84 kDa) isoforms were measured by Western blot analysis using an anti-STAT1 Ab (B, upper panel). The levels of b-actin are shown as a loading control (B, lower panel). (C and D) Suppression of IFN-mediated transactivation activities in the vegf 59UTR-expressing cells. Each stable transfectant was transiently cotransfected with pTK-Renilla (as a monitor for transfection efficiency) and with a luciferase reporter plasmid containing ISRE sequence (C) or GAS sequence (D). Twenty-four hours after transfection, the cells were treated with 500 U/ml rhIFNa (C) or 500 U/ml rhIFNc (D) for 24 h. The luciferase activity of each construct was calculated as LucF/LucR activity. Results are expressed as fold changes compared to untreated cells. Means with different superscripts are significantly different by ANOVA and Scheffé's test (p , 0.05). (E) Resistance to 5-FU and IFNa in the vegf 59UTR-expressing cells. Stable transfectants were untreated or treated with 500 U/ml rhIFNa, 80 lM 5-FU, or 80 lM 5-FU plus 500 U/ml rhIFNa for 48 h. Percentages of apoptotic cells were calculated by the TUNEL-staining method. Values are means 6 SEM, n ¼ 4. Means with different superscripts are significantly different by ANOVA and Scheffé's test (p , 0.05). (F) Resistance to 5-FU and IFNc in the vegf 59UTR-expressing cells. As in (E), but 500 U/ml rhIFNc was used instead of 500 U/ml rhIFNa. Values are means 6 SEM, n ¼ 4. Means with different superscripts are significantly different by ANOVA and Scheffé's test (p , 0.05). doi:10.1371/journal.pmed.0050094.g005 S7A) in our experimental conditions, and found that IFNa did not modify at least these IRES activities ( Figure S7C). At the same time, we also confirmed that IFNa signaling, estimated using the ISRE-dependent transcription reporter assay, was not inhibited in the cells overexpressing bip, c-myc, or fgf-2 59UTR, nor was it inhibited in the cells overexpressing the pdgf-b 59UTR that have no IRES activity ( Figure S7D). Although these results suggest that the suppression of IFN signaling may be specific for the vegf 59UTR, further studies are needed to clarify the molecular mechanism for the suppression.
The IFNs/STAT1 signal is one of the key pathways for tumor suppression. Mice with a targeted deletion of the STAT1 or IFNc receptor develop chemically induced or spontaneous tumors more rapidly than wild-type mice [39]. Similarly, mouse embryonic fibroblasts deficient in the IFNa receptor undergo spontaneous malignant transformation, and the IFNa receptor-deficient mice develop papillomas of the skin at a high rate when treated with a chemical carcinogen [40]. In contrast, the reconstitution of STAT1 suppressed the tumorigenicity of STAT1-deficient tumor cells in vivo, demonstrating that STAT1 acts as an important tumor suppressor [41]. Indeed, the majority of cancer cell lines and primary tumors are resistant to IFNs, often through inhibition of STAT1 expression [42,43]. We propose here that the vegf mRNA 59UTR negatively regulates expression of STAT1, leading to suppression of STAT1-dependent transcriptional activities. It has been suggested that STAT1 directly regulates DNA damage-induced apoptosis by transcriptional activation of apoptosis modulating genes, such as TRAIL, Fas, and XAF-1 [33], all of which were down-regulated in the vegf 59-tumors (Table 1). Thus, the suppression of STAT1 may be crucial for malignant transformation of (B) Increased expression of STAT1 in the stable vegf knockdown cells. Total proteins were extracted from the indicated clones before and 24 h after treatment without or with 500 U/ml IFNa. Amounts of STAT1a and STAT1b isoforms were measured by Western blot analysis using an anti-STAT1 Ab. (C) Enhancement of IFNa-mediated transactivation activity in the stable vegf knockdown cells. Each stable transfectant was transiently cotransfected with pISRE reporter plasmid and pTK-Renilla. Twenty-four hours after transfection, the cells were treated without or with 500 U/ml rhIFNa for 24 h. The luciferase activity of each construct was calculated as firefly luciferase/Renilla luciferase activity. Means with different superscripts are significantly different by ANOVA and Scheffé's test (p , 0.05). doi:10.1371/journal.pmed.0050094.g006 HCT116/vegf 59 cells. In fact, the vegf 59-tumors did not response to IFNa therapy (Figure 7).
Tumor cell growth and survival may require both expression of VEGF and down-regulation of the IFN pathway. Consistent with this notion, it is known that IFNa transcriptionally suppresses VEGF expression [44,45]. In contrast, we suggest here that vegf mRNA may negatively regulate the IFN signaling pathway by repressing STAT1. This reciprocal regulation of VEGF and STAT1 is entirely feasible as these two molecules exert opposing biological functions: VEGF promotes proliferation, metastasis, and angiogenesis [1][2][3][4], and inhibits apoptosis [1]; in contrast, STAT1 negatively regulates proliferation, metastasis, and angiogenesis [41,46], and promotes apoptosis [33,47]. Tumor cells abundantly expressing vegf mRNA [1,48,49] may use this negative regulatory mechanism to gain advantages of growth and survival to escape from the IFN-mediated anti-tumor machinery. Indeed, we found here that stable knockdown of endogenous vegf mRNA by siRNA increased STAT1 expression.
At present, the precise mechanisms for the vegf 59UTRmediated anti-apoptotic action are still unknown. However, our preliminary experiments showed that the vegf 59UTR RNA might interact with double-stranded RNA-activated protein kinase (PKR) protein in the cells expressing the fulllength vegf mRNA or the vegf 59UTR RNA, which were examined by the pull-down assay using an antisense oligonucleotide probe specific for the vegf 59UTR sequence (unpublished data). It is reported that PKR binds several structured UTRs of mRNA, such as the 59UTR of ifn-c mRNA [50], the 39UTR of a-tropomyosin mRNA [51], and the 39UTR of tnf-a mRNA [52]. PKR associates with tumor suppressor, such as IRF-1 and p53 [53] and induces apoptosis. Our preliminary data suggest that the vegf 59UTR might interact with PKR and lead to suppression of PKR-mediated apoptotic pathway. However, this is still an unproven hypothesis, and further experiments are being carried out in our laboratory.
Recent studies have revealed that a large number of noncoding RNAs play a critical role in tumorigenesis [17]. Our findings support the concept originally put forward by Blau and colleagues [18,54] that non-coding regions of mRNAs can act as RNA regulators for tumor malignancy. There is increasing evidence that the UTR of certain mRNAs significantly suppresses the tumorigenic properties of cancer cells both in vitro and in vivo. The 39UTR of a-tropomyosin mRNA suppresses the proliferation, invasion, and destruction of muscle tissues characteristic of rhabdomyosarcoma cells [18]. The 39UTR of ribonucleotide reductase, a key rate-limiting enzyme in DNA synthesis, and the 39UTR of prohibitin, an inhibitor of cell proliferation, significantly suppress the tumorigenic properties and metastatic phenotype of transformed fibroblasts and MCF7 cells [19,20]. In addition, the 59UTR of the human c-myc P0 transcript suppresses the malignant phenotype of human breast cancer cells with decreased anchorage-independent proliferation, enhanced susceptibility to programmed cell death, and complete loss of the ability to form tumors in the intact animal [21]. To the best of our knowledge, the 59UTR vegf mRNA is the first example of tumor-promoting UTR RNA.
VEGF protein is considered to be an important therapeutic target for cancer treatment, and anti-VEGF strategies are undergoing clinical evaluation [14]. A number of preclinical studies have demonstrated that anti-VEGF therapy alone can suppress the growth of established tumors [55,56]. Unlike these preclinical studies, anti-VEGF-specific Ab (bevacizumab) alone has not been shown to increase survival in lung and colorectal cancer patients [14]. The combined use of bevacizumab with standard chemotherapy increased overall survival in metastatic colorectal cancer [57], but did not improve the clinical outcome in metastatic breast cancers in previously treated patients [58]. Furthermore, the combination of the VEGF receptor tyrosine kinase inhibitor, vatalanib, with chemotherapy did not show an increased survival rate in metastatic colorectal cancer patients [59]. Our finding that the novel intrinsic tumor-promoting activity presents in the vegf mRNA might explain, at least in part, the inconsistencies of outcome associated with VEGF-VEGFR strategies. The present study suggests that both vegf mRNA and VEGF protein may synergistically promote the malignancy of tumor cells. Thus anti-vegf transcript therapy, such as siRNA-based gene silencing, in combination with anti-VEGF therapy might provide optimal anti-tumor effects, including inhibition of angiogenesis, blockade of tumor cell survival, and enhanced sensitivity to radiation and drug therapies.    Figure S7. Effect of the vegf 59UTR RNA or IFNa on Cellular IRES Activities (A) Schematic diagram of bicistronic plasmid. The bicistronic cassette expresses the LucR in a cap-dependent manner and LucF in an IRESdependent manner. Each IRES or hairpin control is located between the two cistrons. (B) HCT116 cells were cotransfected with 0.5 lg of the indicated vegf 59UTR-expressing plasmid and 0.25 lg of bicistronic plasmid containing the indicated 59UTR. The each IRES activity was calculated as LucF/LucR activity. (C) IFNa has no effect on cellular IRES activity. HCT116 cells were transfected with the indicated bicistronic plasmid for 24 h, then they were treated with 500 U/ml IFNa for 24 h. The luciferase activity of each construct was calculated as described in (B). (D) Overexpression of IRES-containing 59UTR has no effect on IFNa signaling. HCT116 cells were cotransfected with the indicated 59UTR-CAT-expressing plasmid and luciferase reporter plasmid containing ISRE sequence. Twenty-four hours after transfection, the cells were treated with 500 U/ml rhIFNa for 24 h. The luciferase activity of each construct was measured and calculated as LucF/LucR activity.  Figure S10. Confirmation of the Specificity of Antibody Reactivity Cell extracts were prepared from HCT116 cells treated with 500 U/ml IFN-a (A), or transfected with plasmid expressing L-VEGF (B), or HAtagged VEGF (C). After each extract was either untreated (À) or treated (þ) with antigen peptide, as described in the Methods section, they were subjected to Western blotting. Found at doi:10.1371/journal.pmed.0050094.sg010 (1.1 MB TIF)

Editors' Summary
Background Normally, throughout life, cell division (which produces new cells) and cell death are carefully balanced to keep the body in good working order. But sometimes cells acquire changes (mutations) in their genetic material that allow them to divide uncontrollably to form cancers-disorganized masses of cells. When a cancer is small, it uses the body's existing blood supply to get the oxygen and nutrients it needs for its growth and survival. But, when it gets bigger, it has to develop its own blood supply. This process is called angiogenesis. It involves the release by the cancer cells of proteins called growth factors that bind to other proteins (receptors) on the surface of endothelial cells (the cells lining blood vessels). The receptors then send signals into the endothelial cells that tell them to make new blood vessels. One important angiogenic growth factor is ''vascular endothelial growth factor'' (VEGF). Tumors that make large amounts of VEGF tend to be more abnormal and more aggressive than those that make less VEGF. In addition, high levels of VEGF in the blood are often associated with poor responses to chemotherapy, drug regimens designed to kill cancer cells.
Why Was This Study Done? Because VEGF is a key regulator of tumor development, several anti-VEGF therapies-drugs that target VEGF and its receptors-have been developed. These therapies strongly suppress the growth of tumor cells in the laboratory and in animals but, when used alone, are no better at increasing the survival times of patients with cancer than standard chemotherapy. Scientists are now looking for an explanation for this disappointing result. Like all proteins, cells make VEGF by ''transcribing'' its DNA blueprint into an mRNA copy (vegf mRNA), the coding region of which is ''translated'' into the VEGF protein.
Other, ''noncoding'' regions of vegf mRNA control when and where VEGF is made. Scientists have recently discovered that the noncoding regions of some mRNAs suppress tumor development. In this study, therefore, the researchers investigate whether vegf mRNA has an unrecognized function in tumor cells that could explain the disappointing clinical results of anti-VEGF therapeutics.
What Did the Researchers Do and Find? The researchers first used a technique called small interfering (si) RNA knockdown to stop VEGF expression in human colon cancer cells growing in dishes. siRNAs are short RNAs that bind to and destroy specific mRNAs in cells, thereby preventing the translation of those mRNAs into proteins. The treatment of human colon cancer cells with vegf-targeting siRNAs made the cells more sensitive to chemotherapy-induced apoptosis (a type of cell death).
This sensitivity was only partly reversed by adding VEGF to the cells. By contrast, cancer cells engineered to make more vegf mRNA had increased resistance to chemotherapy-induced apoptosis. Treatment of these cells with an antibody that inhibited VEGF function did not completely block this resistance. Together, these results suggest that both vegf mRNA and VEGF protein have anti-apoptotic effects. The researchers show that the anti-apoptotic activity of vegf mRNA requires a noncoding part of the mRNA called the 59 UTR, and that whereas human colon cancer cells expressing this 59 UTR form tumors in mice, cells expressing a mutated 59 UTR do not. Finally, they report that the expression of several pro-apoptotic genes and of an anti-tumor pathway known as the interferon/STAT1 tumor suppression pathway is downregulated in tumors that express the vegf 59 UTR.
What Do These Findings Mean? These findings suggest that some cancer cells have a survival system that is regulated by vegf mRNA and are the first to show that a 59UTR of mRNA can promote tumor growth. They indicate that VEGF and its mRNA work together to promote their development and to increase their resistance to chemotherapy drugs. They suggest that combining therapies that prevent the production of vegf mRNA (for example, siRNA-based gene silencing) with therapies that block the function of VEGF might improve survival times for patients whose tumors overexpress VEGF.
Additional Information. Please access these Web sites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed. 0050094.
This study is discussed further in a PLoS Medicine Perspective by Hughes and Jones The US National Cancer Institute provides information about all aspects of cancer, including information on angiogenesis, and on bevacizumab, an anti-VEGF therapeutic (in English and Spanish) CancerQuest, from Emory University, provides information on all aspects of cancer, including angiogenesis (in several languages) Cancer Research UK also provides basic information about what causes cancers and how they develop, grow, and spread, including information about angiogenesis Wikipedia has pages on VEGF and on siRNA (note that Wikipedia is a free online encyclopedia that anyone can edit; available in several languages)